Literature DB >> 16766281

The radial artery as a conduit for coronary artery bypass grafting: review of current knowledge.

Petar S Risteski1, Birkan Akbulut, Anton Moritz, Tayfun Aybek.   

Abstract

The effect of coronary artery bypass grafting (CABG) lasts as long as the grafts are patent. The internal mammary artery has been considered the "golden" graft due to the superb long-term patency, exceeding 90% at 10 years. The saphenous vein grafts, unfortunately, tend to occlude with a rate of 10-15% within a year after surgery, and eventually, at 10 years after the operation, as much as 60-70% of these vein grafts are either occluded or have angiographic evidence of atherosclerosis. The search for another "arterial conduit", the radial artery, has intensified through the last 15 years in hope to provide a better graft than the saphenous vein for CABG. This article reviews the current knowledge for the radial artery as a conduit in CABG.

Entities:  

Mesh:

Year:  2006        PMID: 16766281

Source DB:  PubMed          Journal:  Anadolu Kardiyol Derg        ISSN: 1302-8723


  3 in total

1.  Comparison of Sharp Dissection, Electrocautery, and Ultrasonic Activated Scalpel with Regard to Endothelial Damage, Preparation Time, and Postoperative Bleeding During Radial Artery Harvesting.

Authors:  Dinçer Uysal; Şenol Gülmen; Hayrettin Özkan; Ulaş Sağlam; Mustafa Etli; Sema Bircan; Recep Sütçü; Turhan Yavuz; Hakan Öntaş; Fatih Aksoy
Journal:  Braz J Cardiovasc Surg       Date:  2019-12-01

Review 2.  The cardiovascular system and the biochemistry of grafts used in heart surgery.

Authors:  Suna Aydin; Suleyman Aydin; Mehmet Nesimi Eren; Ibrahim Sahin; Musa Yilmaz; Mehmet Kalayci; Orhan Gungor
Journal:  Springerplus       Date:  2013-11-16

3.  Comparison of endothelial function of coronary artery bypass grafts in diabetic and nondiabetic patients: Which graft offers the best?

Authors:  Demet Özkaramanlı Gür; Özcan Gür; Selami Gürkan; Selcem Cömez; Aylin Gönültaş; Murat Yılmaz
Journal:  Anatol J Cardiol       Date:  2015-08       Impact factor: 1.596

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.